This is a best-case-scenario data readout that significantly de-risks the sBLA submission for full approval in Q4 2026. The combination of unprecedented efficacy (eGFR stabilization, 76% risk reduction) and a clean safety profile positions TRUTAKNA as a potential standard-of-care in IgAN. Traders should expect a strong positive reaction and monitor for analyst upgrades and increased institutional interest. The strong commercial launch metrics (350+ patient start forms in 10 weeks) provide additional near-term revenue visibility.
Price Chart
Executive Summary
Vera Therapeutics announced that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 Phase 3 trial in IgA nephropathy (IgAN). The drug demonstrated a 5.6 mL/min/1.73m2 placebo-adjusted difference in mean eGFR change at 52 weeks (p<0.0001), a 76% risk reduction in the composite kidney disease progression endpoint (HR 0.24, p<0.0001), and a favorable safety profile. The company plans to submit a supplemental BLA for full approval in Q4 2026, and reported strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks. This is a transformative data readout that strongly supports the drug's disease-modifying potential and de-risks the path to full approval, representing a major positive catalyst for the stock.
Key Facts
- TRUTAKNA met all prespecified endpoints in the ORIGIN 3 final efficacy analysis (n=428).
- Placebo-adjusted difference in mean eGFR change from baseline at 52 weeks was 5.6 mL/min/1.73m2 (p<0.0001).
- Annualized eGFR slope through 104 weeks showed a placebo-adjusted difference of 5.0 mL/min/1.73m2/year (p<0.0001).
- 76% risk reduction in the composite kidney disease progression endpoint (HR 0.24, 95% CI 0.12-0.48, p<0.0001).
- Zero dialysis, transplant, or death events in the TRUTAKNA arm vs. 8 in placebo through 104 weeks.
- Company plans to submit supplemental BLA for full approval in Q4 2026.
- Over 350 patient start forms generated in the first ten weeks of commercial launch.
- Cash, cash equivalents, and marketable securities of ~$499M as of June 30, 2026, with additional $425M non-dilutive capital available through Oxford Facility.
Financial Impact
Transformative data supports full approval pathway for TRUTAKNA in IgAN, a potential $10B+ U.S. market opportunity. The 76% risk reduction in kidney disease progression and stabilization of eGFR at physiologic rates are best-in-class results that could drive significant market share and peak sales.
Risk Factors
- Full FDA approval is not guaranteed and depends on the sBLA review process in 2027.
- Competition from other IgAN therapies (e.g., sparsentan, iptacopan, other BAFF/APRIL inhibitors) could limit market share.
- Commercial execution risk remains as the launch scales, including payer coverage and physician adoption.
- The $425M Oxford Facility is subject to conditions and may not be fully accessible.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-391280 |
| Document: d32300d8k.htm | 0001193125-26-391280 |
| Document: d32300dex991.htm | 0001193125-26-391280 |
| Document: 0001193125-26-391280-index-headers.html | 0001193125-26-391280 |
| Document: 0001193125-26-391280-index.html | 0001193125-26-391280 |
| Document: 0001193125-26-391280.txt | 0001193125-26-391280 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $33.67 $34.00 | ▲ +0.98% | ▲ +0.16% | $30.13 (−10.53%) |
Aug 10, 2026 7w ago | 8-K | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Aug 10, 2026 7w ago | Press Release | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Jul 9, 2026 12w ago | 8-K | $42.45 $39.12 | ▼ −7.84% | ▼ −7.71% | $30.13 (−29.03%) |
Jul 7, 2026 12w ago | 8-K | $42.96 $43.13 | ▲ +0.40% | ▼ −0.16% | $30.13 (−29.88%) |
Jun 11, 2026 16w ago | Institutional Cluster | $33.65 $35.01 | ▲ +4.04% | ▲ +3.61% | $30.13 (−10.48%) |
Jun 2, 2026 17w ago | 8-K | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
Jun 2, 2026 17w ago | Press Release | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
May 7, 2026 21w ago | 8-K | $35.88 $39.15 | ▲ +9.11% | ▲ +7.61% | $30.13 (−16.04%) |
Feb 26, 2026 31w ago | 8-K | $42.35 $38.85 | ▼ −8.26% | ▼ −7.14% | $30.13 (−28.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access